MannKind Corp. (MNKD)

[SurgeGuy2.0]

Not Looking Good For MNKD!

Afrezza will be viewed as a commercial disappointment if it fails to gain significant market share or grow the mealtime insulin market over the next months and quarters. If you have the ability, watch weekly, monthly and quarterly IMS prescription data (or Symphony Health prescription-tracking data, if that's your preference.)

Afrezza will also draw invariable comparisons to the last, failed inhaled insulin -- Pfizer's (PFE) Exubera. For reference sake, Exubera was approved in January 2006 and launched in September 2006 (delayed due to manufacturing issues.) In October 2007, Pfizer pulled Exubera from the market due to poor sales. Through the first nine months of 2007, Exubera sales were only $12 million.

This thing could flop Big Time and they would still be in debt for Billions and owe their partner Millions! Ouch.

http://www.thestreet.com/story/13045219/1/biotech-stock-mailbag-mannkind-mast-therapeutics-bluebird.html?puc=TSMKTWATCH&cm_ven=TSMKTWATCH